2007 Fiscal Year Final Research Report Summary
Study of Cannabinoid Receptor Agonist in Asthma Therapy
| Project/Area Number |
18591202
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Dokkyo Medical University |
|---|
Principal Investigator |
SHIGEMI Yoshihara Dokkyo Medical University, Pediatrics, Associate Professor (80220713)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ABE Toshio Dokkyo Medical University, Pediatrics, Research Associate (40221048)
YAMADA Yumi Dokkyo Medical University, Pediatrics, Research Associate (00306200)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | Cannabinoid agonist / WIN55212-2 / guinea pig / airway inflammation / asthma / neurosenic inflammation / therapy |
|---|
| Research Abstract |
We investigated that Cannabinoid receptor agonist (WIN55212-2) inhibits antigen-induced plasma extravasation by in guinea pig airways. Plasma extravasation was assessed by the photometric measurement of the extravasated Evans blue after formamide extravasation. In sensitized guinea pigs pretreated with phosphoramidon, WIN55212-2 (0.1 mg/kg iv) significant/7 inhibited plasma extravasation evoked by ovalbumin aerosol (5%, 2min) by 87.2% in the trachea and 66.5% in the main bronchi. Pretreated with WIN55212-2 (0.1, 0.01 and 0.001mg/kg iv) dose-dependentry reduced antigen-induced plasma extravasation in the sensitized guinea pig trachea and main bronchi. A cannabinoid CB2 receptor antagonist, SR144528, reduced the inhibitory effects of WIN55212-2, but not a cannabinoid CB1 receptor antagonist, SR141716A. These findings suggest that WIN55212-2 inhibits the activation of C-fibers via cannabinoid CB2 receptors and reduced airway neurogenic inflammatory reactions in vivo.
|
